journal article·2020-07-29

Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery

Niko Kimura, Masatoshi Maeki, Yusuke Sato, Akihiko Ishida, Hirofumi Tani, Hideyoshi Harashima, Manabu Tokeshi

ACS Applied Materials & Interfaces· Volume 12· Issue 30
Publisher page

Abstract

Microfluidic methodologies for preparation of lipid nanoparticles (LNPs) based on an organic solvent injection method enable precise size control of the LNPs. After preparation of LNPs, the organic solvent injection method needs some post-treatments, such as overnight dialysis or direct dilution with a buffer solution. LNP production using the microfluidic-based organic solvent injection method is dominated by kinetics rather than thermodynamics. Kinetics of ethanol removal from the inner and outer membranes of LNPs could induce a structural change in the membrane that could lead to fusion of LNPs. However, the effects of microfluidic post-treatment on the final size of LNPs have not been sufficiently understood. Herein, we investigated the effect of the post-treatment processes on the final product size of LNPs in detail. A simple baffle device and a model lipid system composed of a neutral phospholipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, POPC) and cholesterol were used to produce the LNPs. We demonstrated that flow conditions of the post-treatment diluting the remaining ethanol in the LNP suspension affected the final product size of LNPs. Based on the findings, we developed an integrated baffle device composed of an LNP production region and a post-treatment region for a microfluidic-based LNP production system; this integrated baffle device prevented the undesirable aggregation or fusion of POPC LNPs even for the high-lipid-concentration condition. Finally, we applied our concept to small interfering RNA (siRNA) delivery and confirmed that no significant effects due to the continuous process occurred on the siRNA encapsulation efficiency, biological distribution, and knockdown activity. The microfluidic post-treatment method is expected to contribute to the production of LNPs for practical applications and the development of novel LNP-based nanomedicines.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Graduate School of Chemical Sciences and Engineering, Hokkaido University, Kita 13, Nishi 8, Kita-ku, Sapporo 060-8628, Japan

Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13, Nishi 8, Kita-ku, Sapporo 060-8628, Japan

JST PRESTO, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita, 12 Nishi 6, Kita-ku, Sapporo 060-0812, Japan

Innovative Research Center for Preventive Medical Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan

Institute of Nano-Life Systems, Institutes of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan

Funding

Ministry of Education, Culture, Sports, Science and Technology · Hosokawa Powder Technology Foundation · Core Research for Evolutional Science and Technology · Precursory Research for Embryonic Science and Technology · Japan Society for the Promotion of Science · Small and Medium Enterprise Agency · Faculty of Engineering, Hokkaido University

References (37)

Show source-provided references
1. 10.1002/anie.20140303610.1002/anie.201403036 ↗
2. 10.1124/pr.115.01207010.1124/pr.115.012070 ↗
3. 10.1016/j.addr.2017.09.01310.1016/j.addr.2017.09.013 ↗
4. 10.3390/nano904063810.3390/nano9040638 ↗
5. 10.1021/acs.molpharmaceut.9b0118210.1021/acs.molpharmaceut.9b01182 ↗
6. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
7. 10.1016/j.jconrel.2016.03.01910.1016/j.jconrel.2016.03.019 ↗
8. 10.1615/CritRevTherDrugCarrierSyst.v26.i6.1010.1615/CritRevTherDrugCarrierSyst.v26.i6.10 ↗
9. 10.1016/j.ijpharm.2015.08.04410.1016/j.ijpharm.2015.08.044 ↗
10. 10.1016/0005-2736(92)90136-A10.1016/0005-2736(92)90136-A ↗
11. 10.1021/nn901676x10.1021/nn901676x ↗
12. 10.1039/C7LC00242D10.1039/C7LC00242D ↗
13. 10.1016/j.addr.2018.03.00810.1016/j.addr.2018.03.008 ↗
14. International Conference Harmonisation of Technical Requirements for registration of Pharmaceuticals for Human Use (ICH) guideline Q3C (R6) on impurities: guideline for residual solvents-step 5; ICH, Aug. 2019.
15. Kimura N. · 2019 · 12310.1016/B978-0-12-812659-2.00005-3 ↗
16. 10.1021/la204833h10.1021/la204833h ↗
17. 10.1021/ja301621z10.1021/ja301621z ↗
18. 10.1039/C5RA04690D10.1039/C5RA04690D ↗
19. 10.1021/acsomega.8b0034110.1021/acsomega.8b00341 ↗
20. 10.1166/jcsb.2012.102010.1166/jcsb.2012.1020 ↗
21. 10.1021/jp808041z10.1021/jp808041z ↗
22. 10.1016/j.bpj.2011.07.01310.1016/j.bpj.2011.07.013 ↗
23. 10.1155/2017/740942010.1155/2017/7409420 ↗
24. 10.1208/pt07023210.1208/pt070232 ↗
25. 10.1016/j.bpj.2016.11.320510.1016/j.bpj.2016.11.3205 ↗
26. 10.1021/jz400857z10.1021/jz400857z ↗
27. 10.1021/nn501294610.1021/nn5012946 ↗
28. 10.1016/0005-2736(95)80014-710.1016/0005-2736(95)80014-7 ↗
29. 10.1016/j.jconrel.2012.09.00910.1016/j.jconrel.2012.09.009 ↗
30. 10.1021/ar010110q10.1021/ar010110q ↗
31. 10.1039/c2sm26546j10.1039/c2sm26546j ↗
32. 10.1021/acsbiomaterials.7b0057210.1021/acsbiomaterials.7b00572 ↗
33. 10.1016/j.nano.2016.09.01410.1016/j.nano.2016.09.014 ↗
34. 10.1016/0005-2736(76)90402-810.1016/0005-2736(76)90402-8 ↗
35. 10.1371/journal.pone.018796210.1371/journal.pone.0187962 ↗
36. 10.1021/acsnano.8b0151610.1021/acsnano.8b01516 ↗
37. 10.1039/C9NR02004G10.1039/C9NR02004G ↗